Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Taysha Gene Therapies Inc

Company price
4.09 USD 0.09 ( 2.25%)
Last update at 2026-11-18T15:01:00Z
VOLUME
315928
Market Cap
1648.72M

Momentum Score

…

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.99
Low
4.19
High
52 Week Price Range
2.71
Low
7.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
4.00
Dividend Yield
-
Revenue TTM
5.49M
Revenue Per Share
0.01
Gross Profit TTM
5.49M
Debt / Equity
0.07
ROE
-47.06%
Net Debt
-301.60M
ROCE
-34.39%
Diluted EPS TTM
-0.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -109.00M -89.30M -111.57M -166.01M -174.52M
Net income -109.00M -89.30M -111.57M -169.58M -175.46M
Selling general administrative 33.87M 28.95M 30.05M 37.36M 41.32M
Selling and marketing expenses - - 1.37M - -
Gross profit 9.77M 8.33M 15.45M 2.50M -
Reconciled depreciation 1.15M 1.25M 1.37M 1.17M 0.49M
Ebit -108.93M -89.20M -106.57M -162.45M -173.27M
Ebitda -107.79M -87.95M -105.20M -125.80M -173.09M
Depreciation and amortization 1.15M 1.25M 1.37M 36.65M 0.17M
Operating income -110.50M -91.46M -72.44M -162.45M -173.27M
Other operating expenses 120.27M 99.79M 87.89M 128.53M 173.27M
Interest expense 0.06M 0.10M 5.00M 3.80M 1.43M
Interest income 9.22M 6.94M 1.85M 0.25M 0.17M
Net interest income 9.16M 6.84M -3.74M -3.55M -1.26M
Income tax expense - -89.30M 1.20M 3.57M 0.94M
Total revenue 9.77M 8.33M 15.45M 2.50M 0.00M
Total operating expenses 120.27M 99.79M 87.89M 128.53M 173.27M
Cost of revenue 1.15M 1.25M 1.37M - -
Total other income expense net 1.50M 2.16M -39.13M -3.57M -1.26M
Net income from continuing ops -109.00M -89.30M -214.38M -166.01M -174.52M
Net income applicable to common shares - - - - -174.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 343.32M 160.36M 266.99M 126.28M 213.96M
Other current assets 4.88M 3.09M 4.80M 8.54M 10.50M
Total liab 96.38M 88.84M 192.06M 125.33M 118.57M
Total stockholder equity 246.94M 71.53M 74.94M 0.95M 95.38M
Other current liab 20.28M 10.98M 10.64M 16.77M 29.98M
Common stock 0.00M 0.00M 0.00M 0.00M -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -711.30M -602.30M -513.01M -401.44M -235.65M
Other liab - - - 4.13M 3.73M
Other assets - - - 3.95M 3.74M
Cash 319.77M 139.04M 144.39M 87.88M 149.10M
Total current liabilities 26.55M 26.23M 36.76M 62.79M 51.75M
Current deferred revenue - 9.77M 18.11M 33.56M -
Net debt -301.60M -75.86M -83.28M -27.95M -86.01M
Short term debt - 1.88M 1.65M 1.52M -
Short long term debt total 18.17M 63.18M 61.11M 59.93M 63.09M
Other stockholder equity 958.43M 677.86M 587.94M 402.39M 331.03M
Property plant equipment - - - - 50.61M
Total current assets 324.65M 142.13M 149.19M 96.42M 159.60M
Net tangible assets - - - - 95.38M
Long term debt 50.11M 43.94M 40.51M 37.97M 37.19M
Accounts payable 6.28M 3.59M 6.37M 10.95M 21.76M
Accumulated other comprehensive income -0.19M -4.03M 0.00M - -
Non currrent assets other 0.18M 2.37M 0.98M 3.95M 3.74M
Non current assets total 18.67M 18.23M 117.81M 29.86M 54.35M
Capital lease obligations 20.04M 19.24M 20.60M 21.96M 25.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.36M -9.71M -24.93M -21.55M
Change to liabilities - - - 33.56M 14.49M
Total cashflows from investing activities -0.60M -0.36M -7.35M -24.93M -21.55M
Net borrowings 9.24M 0.00M -3.45M - 39.96M
Total cash from financing activities 274.59M 76.68M 136.39M 52.10M 39.08M
Change to operating activities - - - -7.24M 14.17M
Net income -109.00M -89.30M -111.57M -166.01M -174.52M
Change in cash 180.90M -4.90M 56.02M -61.22M -99.51M
Begin period cash flow 141.64M 146.54M 90.52M 151.74M 251.25M
End period cash flow 322.53M 141.64M 146.54M 90.52M 151.74M
Total cash from operating activities -93.09M -81.22M -73.02M -88.39M -117.04M
Issuance of capital stock 264.31M 76.78M 182.82M 53.24M 0.00M
Depreciation 1.15M 1.25M 1.37M 1.17M 0.49M
Other cashflows from investing activities 0.13M 0.01M -3.48M -0.06M -0.06M
Other cashflows from financing activities -0.34M -0.10M -0.95M -1.15M 39.08M
Change to netincome - - - 57.93M 28.32M
Capital expenditures 0.74M 0.37M 7.37M 24.87M 21.55M
Change in working capital -5.37M -12.47M -18.01M 18.52M 28.67M
Stock based compensation 13.30M 13.10M 7.91M 18.04M 18.18M
Other non cash items 6.83M 6.19M 47.28M 39.89M 10.14M
Free cash flow -93.83M -81.60M -80.39M -113.26M -138.60M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TSHA
Taysha Gene Therapies Inc
0.09
2.25%
4.09 - - 300.59 4.22 225.23 -0.61
NVO
Novo Nordisk A/S
-0.64
1.57%
40.06 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
8.09
1.51%
542.29 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.85
0.30%
960.62 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

3000 Pegasus Park Drive, Dallas, TX, United States, 75247

214 612 0000

99

Name Title Year Born
Mr. R. A. Session II Founder, Pres, CEO & Director 1979
Mr. Kamran Alam CPA, M.B.A. Chief Financial Officer 1978
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M Chief Medical Officer and Head of R&D 1970
Mr. Frederick Porter Ph.D. Chief Technical Officer NA
Mr. Jim Rouse Chief Information Officer NA
Ms. Tracy M. Porter Chief People Officer NA
Ms. Emily McGinnis M.P.H. Chief Patient Officer & Head of Gov. Affairs NA
Ms. Mishima Gerhart Chief Regulatory Officer & Head of Quality NA
Mr. Sean McAuliffe Chief Commercial Officer NA
Mr. Greg Gara Sr. VP of Manufacturing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…